Nemec Sarah

SVP Finance Nemec buys 125 BOLT shares at $4.61; prior trades at BOLT showed 90d returns of +1567.7% and +1971.2%.

Sarah Nemec, Senior VP Finance and PAO, purchased 125 shares at $4.61 on 2025-12-05, increasing her holdings to 1,415 shares (+9.7%). Her prior two purchases at BOLT (2024-12-16 and 2024-06-06) delivered exceptional 90-day returns of +1567.7% and +1971.2% respectively, establishing a strong track record of well-timed entry points at this ticker. However, the company's fundamentals remain challenged: latest-quarter revenue was $2,169,000.00 with net income of $-7,144,000.00, annual revenue contracted -2.4%, and the company posted a negative full-year net income. The current price of $5.48 sits -46.3% from the 52-week high of $10.20 and only +18.8% above the $4.61 transaction price, reflecting continued weakness despite her demonstrated historical timing acumen at this ticker.

CFO Sarah Nemec bought 125 shares at $5.49; prior BOLT buys delivered 1994.7% & 2162.3% 90d returns, but fundamentals deteriorating: -$8.6M net loss, $1.8M revenue, -2.4% YoY growth.

Sarah Nemec (Senior VP, Finance and PAO) purchased 125 shares at $5.49 on 2025-06-06, bringing holdings to 23.9K shares. Her prior trades at BOLT have been exceptionally well-timed: a buy on 2024-12-16 returned 1994.7% over 90 days, and a buy on 2024-06-06 returned 2162.3% over 90 days. However, this timing success must be weighed against deteriorating fundamentals: the latest quarter shows revenue of $1.8M and a net loss of $-8.6M, while annual revenue declined 2.4% year-over-year and the company remains unprofitable. The stock is currently 55.8% below its 52-week high of $13.59, trading at $6.00. This transaction signals potential conviction given her documented success at this ticker, yet the company's negative profitability and shrinking revenue raise questions about the sustainability of prior gains.

Senior VP Sarah Nemec purchases 5,000 shares in 2 transactions at $0.50 and $0.64 while stock down 74.0% from 52-week high.

Sarah Nemec, Senior VP Finance and PAO at Bolt Biotherapeutics, executed 2 separate purchases totaling 5,000 shares for $2,834.75 between December 2024 and June 2024, increasing her holdings by 56.4%. The purchases occurred at prices well below the current level of $6.92 and the 52-week high of $26.60. The timing of these transactions relative to the company's financial performance is notable: Bolt reported revenue of $1,141,000.00 in its latest quarter and a net loss of $-15,176,000.00 for its most recent full fiscal year, while revenue contracted 2.4% year-over-year. The insider buying at depressed valuation levels warrants attention, though the company's unprofitability and significant recent stock decline (-26.4% over 90 days) place this purchase in context of broader operational and market challenges.